Lenz Therapeutics Raises $47M in Series A Financing
- Lenz Therapeutics, a San Diego, CA-based biopharmaceutical company, raised $47m in Series A funding
- Backers included Versant Ventures and RA Capital Management
- The company intends to use the funds to progress its lead asset, an eyedrop formulation of aceclidine, towards an NDA submission for the treatment of presbyopia
- The company is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision
- Its lead program, aceclidine, is an eye drop designed to restore the loss of near vision associated with presbyopia
- Aceclidine is an NCE in the U.S. and has an established safety profile from its prior use in Europe for glaucoma
